TISIDB

Summary
Symbol	SORD
Name	sorbitol dehydrogenase
Aliases	HEL-S-95n1; L-iditol 2-dehydrogenase; epididymis secretory sperm binding protein Li 95n
Chromosomal Location	15q15-q21.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Mitochondrion membrane Peripheral membrane protein Cell projection, cilium, flagellum Note=Associated with mitochondria of the midpiece and near the plasma membrane in the principal piece of the flagellum. Also found in the epididymosome, secreted by the epididymal epithelium and that transfers proteins from the epididymal fluid to the sperm surface.
Domain	PF08240 Alcohol dehydrogenase GroES-like domain PF00107 Zinc-binding dehydrogenase
Function	Converts sorbitol to fructose. Part of the polyol pathway that plays an important role in sperm physiology. May play a role in the sperm motility by providing an energetic source for sperm.

> Gene Ontology [ TOP ]
Biological Process	GO:0005996 monosaccharide metabolic process GO:0006000 fructose metabolic process GO:0006006 glucose metabolic process GO:0006059 hexitol metabolic process GO:0006060 sorbitol metabolic process GO:0006062 sorbitol catabolic process GO:0006063 uronic acid metabolic process GO:0006064 glucuronate catabolic process GO:0006066 alcohol metabolic process GO:0006970 response to osmotic stress GO:0009991 response to extracellular stimulus GO:0010035 response to inorganic substance GO:0010038 response to metal ion GO:0016051 carbohydrate biosynthetic process GO:0016052 carbohydrate catabolic process GO:0016054 organic acid catabolic process GO:0019318 hexose metabolic process GO:0019319 hexose biosynthetic process GO:0019400 alditol metabolic process GO:0019405 alditol catabolic process GO:0019407 hexitol catabolic process GO:0019519 pentitol metabolic process GO:0019527 pentitol catabolic process GO:0019585 glucuronate metabolic process GO:0019640 glucuronate catabolic process to xylulose 5-phosphate GO:0019751 polyol metabolic process GO:0030317 flagellated sperm motility GO:0031667 response to nutrient levels GO:0042493 response to drug GO:0044262 cellular carbohydrate metabolic process GO:0044275 cellular carbohydrate catabolic process GO:0044282 small molecule catabolic process GO:0044283 small molecule biosynthetic process GO:0044723 single-organism carbohydrate metabolic process GO:0044724 single-organism carbohydrate catabolic process GO:0046164 alcohol catabolic process GO:0046174 polyol catabolic process GO:0046364 monosaccharide biosynthetic process GO:0046370 fructose biosynthetic process GO:0046395 carboxylic acid catabolic process GO:0046686 response to cadmium ion GO:0046688 response to copper ion GO:0051160 L-xylitol catabolic process GO:0051164 L-xylitol metabolic process GO:0051167 xylulose 5-phosphate metabolic process GO:0072329 monocarboxylic acid catabolic process GO:0097722 sperm motility GO:1901159 xylulose 5-phosphate biosynthetic process GO:1901615 organic hydroxy compound metabolic process GO:1901616 organic hydroxy compound catabolic process GO:1990267 response to transition metal nanoparticle
Molecular Function	GO:0003939 L-iditol 2-dehydrogenase activity GO:0016614 oxidoreductase activity, acting on CH-OH group of donors GO:0016616 oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor GO:0030246 carbohydrate binding GO:0031320 hexitol dehydrogenase activity GO:0046526 D-xylulose reductase activity GO:0048037 cofactor binding GO:0050662 coenzyme binding GO:0051287 NAD binding
Cellular Component	GO:0005929 cilium GO:0031514 motile cilium

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa00040 Pentose and glucuronate interconversions hsa00051 Fructose and mannose metabolism hsa01100 Metabolic pathways
Reactome	R-HSA-5661270: Catabolism of glucuronate to xylulose-5-phosphate R-HSA-5652227: Fructose biosynthesis R-HSA-5652084: Fructose metabolism R-HSA-1430728: Metabolism R-HSA-71387: Metabolism of carbohydrates

Summary
Symbol	SORD
Name	sorbitol dehydrogenase
Aliases	HEL-S-95n1; L-iditol 2-dehydrogenase; epididymis secretory sperm binding protein Li 95n
Chromosomal Location	15q15-q21.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between SORD and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	SORD
Name	sorbitol dehydrogenase
Aliases	HEL-S-95n1; L-iditol 2-dehydrogenase; epididymis secretory sperm binding protein Li 95n
Chromosomal Location	15q15-q21.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of SORD in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	SORD
Name	sorbitol dehydrogenase
Aliases	HEL-S-95n1; L-iditol 2-dehydrogenase; epididymis secretory sperm binding protein Li 95n
Chromosomal Location	15q15-q21.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of SORD in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.728	0.0337
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.499	0.796
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.89	0.554
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.426	0.342
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.312	0.847
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.578	0.751
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.113	0.783
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.103	0.948
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.011	0.995
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.125	0.924
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	-0.3	0.881
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.123	0.391

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of SORD in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	3.7	0.27
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	3.7	0.314
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	1

Summary
Symbol	SORD
Name	sorbitol dehydrogenase
Aliases	HEL-S-95n1; L-iditol 2-dehydrogenase; epididymis secretory sperm binding protein Li 95n
Chromosomal Location	15q15-q21.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SORD. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	SORD
Name	sorbitol dehydrogenase
Aliases	HEL-S-95n1; L-iditol 2-dehydrogenase; epididymis secretory sperm binding protein Li 95n
Chromosomal Location	15q15-q21.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SORD. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SORD. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	SORD
Name	sorbitol dehydrogenase
Aliases	HEL-S-95n1; L-iditol 2-dehydrogenase; epididymis secretory sperm binding protein Li 95n
Chromosomal Location	15q15-q21.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SORD. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	SORD
Name	sorbitol dehydrogenase
Aliases	HEL-S-95n1; L-iditol 2-dehydrogenase; epididymis secretory sperm binding protein Li 95n
Chromosomal Location	15q15-q21.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of SORD expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	SORD
Name	sorbitol dehydrogenase
Aliases	HEL-S-95n1; L-iditol 2-dehydrogenase; epididymis secretory sperm binding protein Li 95n
Chromosomal Location	15q15-q21.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between SORD and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	SORD
Name	sorbitol dehydrogenase
Aliases	HEL-S-95n1; L-iditol 2-dehydrogenase; epididymis secretory sperm binding protein Li 95n
Chromosomal Location	15q15-q21.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting SORD collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting SORD.

ID	Name	Drug Type	Targets	#Targets
DB00157	NADH	Small Molecule	AASS, ACADS, ADH1A, ADH1B, ADH1C, ADH4, ADH5, ADH7, AKR1B1, AKR1C1 ......	144
DB04478	Cp-166572, 2-Hydroxymethyl-4-(4-N,N-Dimethylaminosulfonyl-1-Piperazino)-Pyrimidine	Small Molecule	SORD	1

Browse SORD